IL2 and neoplasm: Importantly, the combination therapy enhanced CD4+ and CD8+ T-cell infiltration, increased the production of pro-inflammatory cytokines such as IL-2, and reduced the expression of immunosuppressive factors such as IL-6, indicating an immunomodulatory effect that improved anti-tumor immunity.